
Annual report 2022
added 03-29-2023
Chembio Diagnostics Revenue 2011-2026 | CEMI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.5 M | 47.8 M | 30.5 M | 34.5 M | 33.4 M | 24 M | 17.9 M | 24.3 M | 27.6 M | 29.5 M | 25.6 M | 19.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.5 M | 17.9 M | 30.3 M |
Quarterly Revenue Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 11.2 M | - | 18.8 M | - | 12.1 M | 6.46 M | 8.72 M | - | 10.3 M | 5.11 M | 6.86 M | - | 9.72 M | 9.89 M | 8.54 M | - | 34.6 M | 8.96 M | 7.72 M | 5.99 M | 7.59 M | 4.11 M | 6.33 M | 4.25 M | 3.75 M | 3.27 M | 6.6 M | 4.42 M | 6.89 M | 6.72 M | 6.23 M | - | 7.31 M | 7.42 M | 5.81 M | - | 9.62 M | 5.39 M | 6.68 M | - | 5.01 M | 6.08 M | 6.65 M | - | 5.92 M | 3.61 M | 3.64 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.6 M | 3.27 M | 7.85 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioNano Genomics
BNGO
|
28.5 M | $ 1.14 | 0.44 % | $ 6.21 M | ||
|
Burning Rock Biotech Limited
BNR
|
508 M | $ 16.07 | 1.39 % | $ 173 M | ||
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
6.32 B | $ 115.09 | 0.03 % | $ 35 B | ||
|
Interpace Biosciences
IDXG
|
38.7 M | $ 2.25 | -2.17 % | $ 9.95 M | ||
|
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | ||
|
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
380 M | $ 16.32 | 1.65 % | $ 870 M | ||
|
Medpace Holdings
MEDP
|
2.53 B | $ 498.22 | 0.95 % | $ 14.4 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M | ||
|
Myriad Genetics
MYGN
|
824 M | $ 4.45 | 2.3 % | $ 412 M | ||
|
NeoGenomics
NEO
|
727 M | $ 7.87 | 2.34 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
622 K | $ 1.4 | 2.19 % | $ 1.86 M | ||
|
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
332 M | $ 23.05 | -0.35 % | $ 640 M | ||
|
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | ||
|
Senseonics Holdings
SENS
|
35.3 M | $ 6.62 | -0.9 % | $ 276 M | ||
|
Charles River Laboratories International
CRL
|
4.02 B | $ 176.51 | 0.49 % | $ 8.75 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | ||
|
Soleno Therapeutics
SLNO
|
190 M | $ 52.58 | -0.1 % | $ 2.67 B | ||
|
Danaher Corporation
DHR
|
24.6 B | $ 190.99 | 0.73 % | $ 136 B | ||
|
Neuronetics
STIM
|
149 M | $ 1.37 | 1.11 % | $ 90.4 M | ||
|
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
4.37 B | $ 122.69 | 1.46 % | $ 19.5 B | ||
|
Fulgent Genetics
FLGT
|
283 M | $ 14.96 | 3.67 % | $ 452 M | ||
|
Thermo Fisher Scientific
TMO
|
44.6 B | $ 500.25 | 0.83 % | $ 189 B | ||
|
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.69 | -3.28 % | $ 61.9 M | ||
|
Guardant Health
GH
|
982 M | $ 79.27 | 0.85 % | $ 9.94 B | ||
|
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
377 M | $ 48.44 | 1.11 % | $ 2.9 B | ||
|
Anixa Biosciences
ANIX
|
210 K | $ 2.73 | 1.49 % | $ 88.6 K | ||
|
Biomerica
BMRA
|
5.31 M | $ 2.1 | -2.1 % | $ 4.82 M | ||
|
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | ||
|
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 28.26 | -0.18 % | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
5.48 B | $ 107.45 | 0.59 % | $ 8.86 B | ||
|
Laboratory Corporation of America Holdings
LH
|
14 B | $ 261.12 | 0.07 % | $ 21.7 B | ||
|
Natera
NTRA
|
820 M | $ 197.55 | 2.34 % | $ 19.4 B | ||
|
Lantheus Holdings
LNTH
|
1.54 B | $ 80.41 | -0.23 % | $ 5.43 B | ||
|
Waters Corporation
WAT
|
932 M | $ 318.26 | -0.54 % | $ 19 B |